There exists a high unmet need in osteoarthritis (OA) patients, an aspect that underpins the evolution of the osteoarthritis therapeutics market. The growing health and economic burden of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is a key trend in the OA therapeutics market. Researchers have made continuous headways in identification of potential therapeutic targets. Of note, biological therapies present an incredible prospect for market players. A number of ongoing randomized controlled trials are key to new avenues waiting to be explored in the OA therapeutics market. In particular, a number of disease-modifying OA drugs have come to the fore. Emergence of nerve growth factor inhibitors is a promising therapeutics for OA-related pain.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7155
The landscape of osteoarthritis therapeutics market is expected to be shaped by relentless efforts of players in navigating the clinical heterogeneity of OA. The development of disease-modifying OA drugs in this regard presents an interesting avenue. Growing research on expanding the understanding of pathogenesis of OA will open up new avenues.
Need for innovative Approaches Based on In Vitro and In Vivo Models
Rapidly aging populations in several parts of the world will have impact on increasing the prevalence of AO in near future. This is calling for innovative approaches so far as OA therapeutics is concerned. In recent years, mesenchymal stromal cell (MSCs) or exosome-based approaches show high promise. Novel strategies on microRNA (miRNA) are another area which holds high revenue in the osteoarthritis therapeutics market. New emerging experimental strategies focus on Hyaluronan (HA) formulations to target pathogenesis, despite the fact that the related understanding is still in preliminary stages. Growing studies on autologous regenerative cells will open new avenues in the osteoarthritis therapeutics market. Such developments will be driven by strides in vitro and in vivo OA studies.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7155
Some of the key players in the market are Flexion Therapeutics, Inc., GlaxoSmithKline PLC., Sanofi S.A., Kitov Pharmaceuticals Ltd., and Horizon Therapeutics PLC.